| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Former Director
2 companies
Sunil Patel last filed a Form 4 in June 2023, as Director at OABI. The filings on record cover 2 companies.
At the last filing, the largest reported position was 28,820 shares of LGND. The LGND filings lean toward selling, a net 44,878 shares.
Sunil Patel has 17 Form 4 filings on record from March 2015 to June 2023, across 2 companies: Director at OmniAb (OABI), 2022–2023; Former Director at Ligand Pharmaceuticals (LGND), 2015–2022.
The 41 reported transactions were 20 option or other derivative awards, 10 stock awards, 4 option exercises and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $298K and 2 sales worth about $10.5M.
The largest open-market purchase was 43,000 shares of OABI at an average $2.77 on November 9, 2022, about $119K. Twelve months later OABI was up 58%.
The largest open-market sale was 42,287 shares of LGND at an average $240.05 on August 16, 2018, about $10.2M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2022 | OABI Omniab, Inc. | Director | Buy | 43,000 | $2.77 | $119,110.00 | +24.9% | +45.7% | +58.0% | |
| Nov 2, 2020 | LGND Ligand Pharmaceuticals Inc | Director | Buy | 1,000 | $82.52 | $82,520.00 | +3.7% | - | - | |
| Aug 2, 2019 | LGND Ligand Pharmaceuticals Inc | Director | Buy | 1,000 | $95.98 | $95,980.00 | +3.9% | - | - | |
| Aug 16, 2018 | LGND Ligand Pharmaceuticals Inc | Director | Sale+OE | 42,287 | $240.05 | $10,150,808.29 | -63.3% | - | - | |
| Mar 19, 2015 | LGND Ligand Pharmaceuticals Inc | Director | Sell | 4,591 | $74.42 | $341,662.22 | -11.0% | - | - |